Phase 2 Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are between 18 and 75 years old (inclusive) at the time of signing the consent form (for those in the United States)
- People who have been diagnosed with type 2 diabetes and whose HbA1c blood sugar level falls between 7.0% and 10.0% at the screening visit
- People who are managing their diabetes through diet and exercise alone, or who have been on a steady daily dose of metformin (at least 1000 mg per day) for at least 3 months before the screening visit
- People whose Body Mass Index (BMI) — a measure of body weight relative to height — is between 25 and 50
- People whose body weight has changed by less than 5% in the 3 months before the screening visit
- People who are able and willing to give formal consent to participate and to follow all study procedures
Who may not be able to join:
- People who have type 1 diabetes, or who have used any blood sugar-lowering medications other than metformin in the 3 months before screening
- People whose fasting blood sugar level is above 270 mg/dL, indicating poor blood sugar control
- People who have had diabetic ketoacidosis (a serious diabetes complication) or a severe low blood sugar episode within the past 6 months
- People who have a significant heart condition, such as severe heart failure, a recent heart attack, stroke, or a heart procedure within the past 3 months
- People who have a history of pancreas inflammation (pancreatitis) or other factors that may raise the risk of developing it
- People who have a personal or family history of a specific type of thyroid cancer (medullary thyroid carcinoma) or a related hormonal condition called multiple endocrine neoplasia type 2
- People who have significant liver disease, reduced kidney function (confirm with trial site), or abnormal blood test results at screening
- People who have taken part in another clinical study within the past 30 days (or longer, depending on the study drug used); for studies involving GLP-1 medicines or weight loss treatments, participation within the past 3 months before screening may also be a factor
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-2-410-9147
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Glycated Hemoglobin (HbA1c)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.